---
document_datetime: 2025-12-17 23:30:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/neulasta.html
document_name: neulasta.html
version: success
processing_time: 0.116485
conversion_datetime: 2025-12-28 19:26:42.760001
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Neulasta

[RSS](/en/individual-human-medicine.xml/66728)

##### Authorised

This medicine is authorised for use in the European Union

pegfilgrastim Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Neulasta](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

#### 

Neulasta is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.

It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (neutropenia accompanied by fever).

Neulasta is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in large numbers of abnormal blood cells are produced, which can develop into leukaemia).

Expand section

Collapse section

## How is Neulasta used?

Neulasta can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders.

It is available as a prefilled syringe containing a solution for injection under the skin. Neulasta is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines). Patients can inject themselves if they have been trained appropriately.

For more information about using Neulasta, see the package leaflet or contact your doctor or pharmacist.

## How does Neulasta work?

The active substance in Neulasta, pegfilgrastim, consists of filgrastim, which is very similar to a human protein called granulocyte colony stimulating factor (G?CSF).  Filgrastim works by encouraging the bone marrow to produce more white blood cells, increasing white blood cell counts and so treating neutropenia.

Filgrastim has been available in other medicines in the European Union (EU) for a number of years. In Neulasta, filgrastim has been 'pegylated' (attached to a chemical called polyethylene glycol). This slows down the removal of filgrastim from the body, allowing the medicine to be given less often.

## What benefits of Neulasta have been shown in studies?

Neulasta has been studied in two main studies involving 467 patients with breast cancer who were being treated with chemotherapy. In both studies, the effectiveness of a single injection of Neulasta was compared with multiple daily injections of filgrastim during each of four chemotherapy cycles. The main measure of effectiveness was the duration of severe neutropenia during the first cycle of chemotherapy.

Neulasta was as effective as filgrastim in reducing the duration of severe neutropenia. In both studies, the patients had severe neutropenia for around 1.7 days during their first chemotherapy cycle. This  compares with around five to seven days when no stimulating factor is used.

## What are the risks associated with Neulasta?

The most common side effect with Neulasta (which may affect more than 1 in 10 people) is pain in the bones. Pain in muscles is also common. For the full list of side effects and restrictions with Neulasta, see the package leaflet.

## Why has Neulasta been approved?

Neulasta is effective at reducing the duration of severe neutropenia during chemotherapy and its side effects were considered manageable. The European Medicines Agency decided that Neulasta's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Neulasta?

The company that markets Neulasta will ensure that patients or carers using the medicine are provided with an alert card explaining how to use the injection device that delivers the medicine.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Neulasta have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Neulasta are continuously monitored. Side effects reported with Neulasta are carefully evaluated and any necessary action taken to protect patients.

## Other information about Neulasta

Neulasta received a marketing authorisation valid throughout the EU on 22 August 2002.

Neulasta : EPAR - Medicine overview

Reference Number: EMA/554222/2018

English (EN) (74.27 KB - PDF)

**First published:** 19/06/2009

**Last updated:** 04/10/2018

[View](/en/documents/overview/neulasta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-448)

български (BG) (102.12 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/bg/documents/overview/neulasta-epar-medicine-overview_bg.pdf)

español (ES) (75.48 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/es/documents/overview/neulasta-epar-medicine-overview_es.pdf)

čeština (CS) (97.38 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/cs/documents/overview/neulasta-epar-medicine-overview_cs.pdf)

dansk (DA) (73.72 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/da/documents/overview/neulasta-epar-medicine-overview_da.pdf)

Deutsch (DE) (76.15 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/de/documents/overview/neulasta-epar-medicine-overview_de.pdf)

eesti keel (ET) (73.46 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/et/documents/overview/neulasta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (109.3 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/el/documents/overview/neulasta-epar-medicine-overview_el.pdf)

français (FR) (76.42 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/fr/documents/overview/neulasta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (92.95 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/hr/documents/overview/neulasta-epar-medicine-overview_hr.pdf)

italiano (IT) (74.04 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/it/documents/overview/neulasta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (94.97 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/lv/documents/overview/neulasta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (95.93 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/lt/documents/overview/neulasta-epar-medicine-overview_lt.pdf)

magyar (HU) (94.23 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/hu/documents/overview/neulasta-epar-medicine-overview_hu.pdf)

Malti (MT) (99.41 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/mt/documents/overview/neulasta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (75.43 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/nl/documents/overview/neulasta-epar-medicine-overview_nl.pdf)

polski (PL) (98.49 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/pl/documents/overview/neulasta-epar-medicine-overview_pl.pdf)

português (PT) (75.55 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/pt/documents/overview/neulasta-epar-medicine-overview_pt.pdf)

română (RO) (96.51 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/ro/documents/overview/neulasta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (96.92 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/sk/documents/overview/neulasta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (91.52 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/sl/documents/overview/neulasta-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.59 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/fi/documents/overview/neulasta-epar-medicine-overview_fi.pdf)

svenska (SV) (74.07 KB - PDF)

**First published:**

19/06/2009

**Last updated:**

04/10/2018

[View](/sv/documents/overview/neulasta-epar-medicine-overview_sv.pdf)

Neulasta : EPAR - Risk management plan

English (EN) (3.58 MB - PDF)

**First published:** 03/04/2019

**Last updated:** 08/12/2025

[View](/en/documents/rmp/neulasta-epar-risk-management-plan_en.pdf)

## Product information

Neulasta : EPAR - Product Information

English (EN) (818.91 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 28/06/2024

[View](/en/documents/product-information/neulasta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-474)

български (BG) (957.36 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/bg/documents/product-information/neulasta-epar-product-information_bg.pdf)

español (ES) (876.53 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/es/documents/product-information/neulasta-epar-product-information_es.pdf)

čeština (CS) (947.16 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/cs/documents/product-information/neulasta-epar-product-information_cs.pdf)

dansk (DA) (890.67 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/da/documents/product-information/neulasta-epar-product-information_da.pdf)

Deutsch (DE) (901.09 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/de/documents/product-information/neulasta-epar-product-information_de.pdf)

eesti keel (ET) (866.98 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/et/documents/product-information/neulasta-epar-product-information_et.pdf)

ελληνικά (EL) (960.95 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/el/documents/product-information/neulasta-epar-product-information_el.pdf)

français (FR) (911.6 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/fr/documents/product-information/neulasta-epar-product-information_fr.pdf)

hrvatski (HR) (922.65 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/hr/documents/product-information/neulasta-epar-product-information_hr.pdf)

íslenska (IS) (884.06 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/is/documents/product-information/neulasta-epar-product-information_is.pdf)

italiano (IT) (889.46 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/it/documents/product-information/neulasta-epar-product-information_it.pdf)

latviešu valoda (LV) (924.14 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/lv/documents/product-information/neulasta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (929.95 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/lt/documents/product-information/neulasta-epar-product-information_lt.pdf)

magyar (HU) (946.35 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/hu/documents/product-information/neulasta-epar-product-information_hu.pdf)

Malti (MT) (1015.71 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/mt/documents/product-information/neulasta-epar-product-information_mt.pdf)

Nederlands (NL) (881.24 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/nl/documents/product-information/neulasta-epar-product-information_nl.pdf)

norsk (NO) (875.84 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/no/documents/product-information/neulasta-epar-product-information_no.pdf)

polski (PL) (943.07 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/pl/documents/product-information/neulasta-epar-product-information_pl.pdf)

português (PT) (882.22 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/pt/documents/product-information/neulasta-epar-product-information_pt.pdf)

română (RO) (934.36 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/ro/documents/product-information/neulasta-epar-product-information_ro.pdf)

slovenčina (SK) (951.26 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/sk/documents/product-information/neulasta-epar-product-information_sk.pdf)

slovenščina (SL) (927.65 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/sl/documents/product-information/neulasta-epar-product-information_sl.pdf)

Suomi (FI) (876.87 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/fi/documents/product-information/neulasta-epar-product-information_fi.pdf)

svenska (SV) (878.48 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

28/06/2024

[View](/sv/documents/product-information/neulasta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG1743 28/06/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Neulasta : EPAR - All Authorised presentations

English (EN) (35.56 KB - PDF)

**First published:** 27/04/2009

**Last updated:** 27/06/2023

[View](/en/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-687)

български (BG) (43.25 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/bg/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_bg.pdf)

español (ES) (35 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/es/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.95 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/cs/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.99 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/da/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.26 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/de/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (31.92 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/et/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.11 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/el/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_el.pdf)

français (FR) (36.84 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/fr/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.48 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/hr/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (37.24 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/is/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (34.2 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/it/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.89 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/lv/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.31 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/lt/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (38.89 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/hu/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (40.38 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/mt/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (33.02 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/nl/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (37.72 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/no/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.07 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/pl/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_pl.pdf)

português (PT) (35.28 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/pt/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.5 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/ro/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (38.81 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/sk/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (35.37 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/sl/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (32.37 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/fi/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.52 KB - PDF)

**First published:**

27/04/2009

**Last updated:**

27/06/2023

[View](/sv/documents/all-authorised-presentations/neulasta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Neulasta Active substance pegfilgrastim International non-proprietary name (INN) or common name pegfilgrastim Therapeutic area (MeSH)

- Cancer
- Neutropenia
- Febrile Neutropenia
- Chemotherapy-Induced Febrile Neutropenia

Anatomical therapeutic chemical (ATC) code L03AA13

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## Authorisation details

EMA product number EMEA/H/C/000420 Marketing authorisation holder

Amgen Europe B.V.

Minervum 7061

Opinion adopted 30/05/2002 Marketing authorisation issued 22/08/2002 Revision 41

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Neulasta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (134.98 KB - PDF)

**First published:** 08/12/2025

[View](/en/documents/procedural-steps-after/neulasta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Neulasta : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (272.69 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 08/12/2025

[View](/en/documents/procedural-steps-after/neulasta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Neulasta-H-C-PSUSA-00002326-20190 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/562284/2019

English (EN) (107.13 KB - PDF)

**First published:** 29/11/2019

[View](/en/documents/scientific-conclusion/neulasta-h-c-psusa-00002326-20190-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Neulasta-H-C-420-PSUV-71 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/798931/2013

English (EN) (66.95 KB - PDF)

**First published:** 03/01/2014

**Last updated:** 03/01/2014

[View](/en/documents/scientific-conclusion/neulasta-h-c-420-psuv-71-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Neulasta-H-C-420-P45-51 : EPAR - Assessment Report

Adopted

Reference Number: EMA/257049/2013

English (EN) (741.09 KB - PDF)

**First published:** 17/05/2013

**Last updated:** 17/05/2013

[View](/en/documents/variation-report/neulasta-h-c-420-p45-51-epar-assessment-report_en.pdf)

Neulasta : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (82.2 KB - PDF)

**First published:** 19/06/2009

**Last updated:** 19/06/2009

[View](/en/documents/steps-after-cutoff/neulasta-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Neulasta : EPAR - Scientific Discussion

English (EN) (275.67 KB - PDF)

**First published:** 19/06/2009

**Last updated:** 19/06/2009

[View](/en/documents/scientific-discussion/neulasta-epar-scientific-discussion_en.pdf)

Neulasta : EPAR - Procedural steps taken before authorisation

English (EN) (92.16 KB - PDF)

**First published:** 19/06/2009

[View](/en/documents/procedural-steps/neulasta-epar-procedural-steps-taken-authorisation_en.pdf)

#### More information on Neulasta

- [Risk factors For Bone Pain among Neulasta® Users (20120320) - post-authorisation study](https://catalogues.ema.europa.eu/study/10330)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/12/2025

## Share this page

[Back to top](#main-content)